๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin

โœ Scribed by David B. Smith; Jennifer M. Margison; Samuel B. Lucas; Peter M. Wilkinson; Anthony Howell

Publisher
Springer
Year
1987
Tongue
English
Weight
406 KB
Volume
19
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II clinical and pharmacological st
Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer
โœ Robert Milroy; Jeffrey Cummings; Stanley B. Kaye; Stephen W. Banham ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer ๐ŸŒ English โš– 298 KB

4-Demethoxydaunorubicin (4-DMDNR) is an oral anthracycline with antitumour activity demonstrated in a number of clinical studies. We have assessed the usefulness of 4-DMDNR in 16 patients with advanced small cell lung cancer, none of whom had received previous chemotherapy. There were no complete or

Phase I trial of 4-demethoxydaunorubicin
Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses
โœ S. Kaplan; C. Sessa; Y. Willems; M. A. Pacciarini; V. Tamassia; F. Cavalli ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Springer US ๐ŸŒ English โš– 454 KB

Twenty-four patients with a variety of solid tumors entered a Phase I trial with 4-demethoxydaunorubicin, a new analogue of daunorubicin. The drug was given as a single oral dose of 10-60 mg/m 2 repeated every 3-4 weeks. Leukopenia was the dose-limiting toxicity. Other toxic effects included mild t